ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2047

The Alter of Gut Microbiota in Dialysis Patients and Its Influence on the Prognosis for ESRD Patients

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Zhang, Jun, Department of Nephrology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, GUANG DONG, China
  • Luo, Dan, Department of Nephrology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, GUANG DONG, China
  • Xiong, Haixia, Department of Nephrology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, GUANG DONG, China
  • Li, Hui-qun, Department of Nephrology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, GUANG DONG, China
Background

Previous studies have found that alteration in gut microbiota occurred in end-stage renal disease (ESRD) patients with or without dialysis, and are associated with complications such as inflammation and cardiovascular events. However, it has not been clarified whether gut microbiota are influenced by dialysis intervention in ESRD patients.

Methods

The fecal samples of 73 ESRD patients were collected, including 33 pre-dialysis ESRD patients, 19 peritoneal dialysis (PD) patients, and 21 hemodialysis (HD) patients; 19 healthy fecal samples were also collected as control in this study. The 16S rRNA sequencing and the bioinformatics was used to analyze the the composition and function of gut microbiota. The clinical outcomes of the patients were tracked from April 2017 to the end of May 2020.

Results

Compared with the pre-dialysis patients, Bacteroidetes decreased significantly in HD patients. At the genus level, a total of 14 genera showed differences between patients before and after dialysis. Pre-dialysis patients have a increased abundance of Parabacteroides, Prevetolla and Oscillospira, and the decreased abundance of Lachnospira, Klebsiella, Akkermansia and Roseburia. HD could repair the abnormal changes of these flora in pre-dialysis patients. We could not found any bacteria defference between PD and pre-dialysis patients in phylum and genus level. The PICRUSt analysis showed that PD and HD could change the signal transduction and metabolic pathways of ESRD patients. It was found that Bacteroides and SMB53 were associated with the occurrence of cardiovascular events. Blautia, Faecalibacterium, and Veillonella were associated with peritonitis in PD patients.

Conclusion

Our results suggested that compared with healthy control, the composition and function of gut microbiota of pre-dialysis patients were changed, HD could restored the relative abundance of beneficial bacteria and reduced some potential pathogenic bacteria. Some gut microbiota were associated with prognosis in all of ESRD patients and peritonitis in PD patients.